The doctor hands you a prescription. You fold it, put it in your pocket, and leave. And then - for hundreds of thousands of specialty pharmacy patients - the system collapses. Phone trees. Insurance holds. Prior authorization black holes. Medications that arrive a week late, if they arrive at all.
Ogi Kavazovic spent years in healthcare watching this happen. At Flatiron Health, he was running marketing and product strategy for oncology data - surrounded by cancer patients and the clinical teams trying to help them. The administrative friction between a doctor's intent and a patient's actual access to medication wasn't a policy problem or a coverage problem. It was, at its core, a technology and workflow problem. And Ogi knew how to fix those.
So in 2021, he co-founded House Rx with a premise that sounds almost too simple: what if the pharmacy was inside the clinic? Not a full retail pharmacy. Not a mail-order operation. A medically integrated dispensing model - purpose-built technology that turns oncology practices, rheumatology centers, and specialty clinics into pharmacies for their own patients.
Four years later, House Rx processes approximately $1.5 billion in specialty scripts per year. In November 2025, the company closed a $55 million Series B led by New Enterprise Associates and Town Hall Ventures - bringing total capital raised above $100 million. Time Magazine called House Rx one of the world's top HealthTech companies that year. Ogi would probably say the timing makes sense. The specialty pharmacy market generates roughly $300 billion annually. A few large chains dominate it. And until recently, nobody had built the infrastructure to credibly challenge them from inside the clinic.